Although histamine release can result in inflammation, activation of the H2R is associated with immune suppression; administration of an H2R antagonist during a preexisting proinflammatory condition, such as occurs in MS, may lead to further immune stimulation. Here, HRH2 is linked to myeloid sarcoma.